Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 10.1038/s41591-022-01919-8)

Journal article

Open access

A. Feigin, E. E. Evans, T. L. Fisher, J. E. Leonard, E. S. Smith, A. Reader, V. Mishra, R. Manber, K. A. Walters, L. Kowarski, …

Nature medicine

2022

Files and links (1)

url

https://doi.org/10.1038/s41591-022-02070-0View

Published (Version of record) Open

1 Record Views

Title: Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial (Nature Medicine, (2022), 10.1038/s41591-022-01919-8)
Creators: A. Feigin - New York University
E. E. Evans - Vaccinex
T. L. Fisher - Vaccinex
J. E. Leonard - Vaccinex
E. S. Smith
A. Reader - Vaccinex
V. Mishra - Vaccinex
R. Manber - Ixico
K. A. Walters - Statistics Collaborative
L. Kowarski - Statistics Collaborative
D. Oakes - University of Rochester Medical Center
E. Siemers
K. D. Kieburtz - University of Rochester Medical Center
M. Zauderer - Vaccinex
E. Kayson
J. Goldstein
R. Barbano - Ixico
K. Marder
P. Dayalu
H. D. Rosas
S. Kostyk
J. Kamholz - Vaccinex
B. Racette
J. Bang
D. Claassen
K. McDonell
S. Factor
F. Walker
C. Goas
J. Wojcieszek
L. A. Raymond
J. Corey-Bloom
V. Sung
M. Dean
M. Geshwind
A. Nelson
S. Frank
K. LaFaver
A. Duker - New York University
L. Elmer
A. Samii - Vaccinex
Y. H Lin
S. Chouinard
L. Seeberger
B. Scott
J. Boyd
N. McFarland
E. F. Stimming
O. Suchowersky
C. Testa
K. Anderson
Publication Details: Nature medicine
Identifiers: 991006034849802656
Academic Unit: Neurology
Resource Type: Journal article